RxDoctor Payments Data

Fred Lindsay, DO

Otolaryngology · Hampton, VANPI 1750352316

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,439 of the $9,387 with a category attached, or 89.9%. It is spread thinly across 41 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Among otolaryngology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,387in general payments, 2019–2025

Across 311 payments — averaging $30.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$1K
  • Aerin Medical Inc.$1K
  • Jazz Pharmaceuticals Inc.$961
  • Regeneron Healthcare Solutions, Inc.$906
  • GSK$826
  • Biocryst US Sales Co., LLC$452
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$6046%
  • Food & beverage$8,43990%
  • Education$3143%
  • Other$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,387 in reported general payments places this provider in the 90th percentile of 241 otolaryngology providers in Virginia.

See all otolaryngology providers in Virginia

Medicare billing

Part B allowed, 2024
$284,913
Medicare patients
896
Services billed
10,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab12$51,322
Dupixent PenDupilumab15$49,704
OmnarisCiclesonide11$3,182
Ipratropium Bromide71$2,632
Ofloxacin26$1,429
Montelukast Sodium96$1,170
Fluticasone Propionate71$653
Scopolamine15$590
Azelastine Hcl28$378
Famotidine34$332
Levothyroxine Sodium19$294
Omeprazole33$253
Cephalexin26$239
Meclizine Hcl13$221
Prednisone64$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala$826$51,32212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 241 otolaryngology providers in Virginia.

Other otolaryngology in Hampton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →